Intervention

Dacomitinib

ClinicalTrials.gov intervention label

Clinical trials17

Recruiting1

Common conditions25

Lead sponsors shown10

Clinical trials

17 shown

First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R MutationsNCT05271916 · 2022-10-13

Real World Utilization and Outcomes With Dacomitinib First Line Treatment for EGFR Mutation-positive Advanced Non Small Cell Lung Cancer Among Asian Patients - A Multi Center Chart ReviewNCT04609319 · 2021-06-11

Dacomitinib in Lung Cancer With Uncommon EGFR MutationsNCT04504071 · 2020-12-08

ACTIVE_NOT_RECRUITING

Central Nervous System(CNS) Efficacy of DacomitinibNCT04675008 · 2020-12-07

Bevacizumab Plus EGFR-TKIs in Chinese Patients With EGFR-mutant NSCLC: a Real-world StudyNCT04575415 · 2020-10-07

Dacomitinib Treatment Followed by 3rd Generation EGFR-TKI in Patients With EGFR Mutation Positive Advanced NSCLCNCT04768491 · 2020-09-01

Dacomitinib for Treatment of Patients in India With Metastatic Non Small Cell Lung Cancer With EGFR Activating MutationsNCT04511533 · 2020-08-27

An Open Label, Multicenter, Phase II Study of Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain MetastasesNCT04339829 · 2020-08-01

Best EGFR-TKI Sequence in NSCLC Harboring EGFR MutationsNCT04811001 · 2020-06-12

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialNCT03878524 · 2020-04-01

Phase 2 Study of Dacomitinib in NSCLCNCT04027647 · 2019-09-11

ACTIVE_NOT_RECRUITING

Study of Dacomitinib and Osimertinib for Patients With Advanced EGFR Mutant Lung CancerNCT03810807 · 2019-01-17

A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib.NCT03755102 · 2018-11-21

Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant NSCLCNCT02039336 · 2014-04-02

A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)NCT01920061 · 2013-09-10

A Study Of Dacomitinib (PF-00299804) In Patients With Advanced Non-Small Cell Lung CancerNCT01858389 · 2013-07-01

Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRONCT01465802 · 2011-12-26

Common conditions

Lung Cancer2 NSCLC2 NSCLC Stage IIIB2 NSCLC Stage IV2 Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive1 Anatomic Stage IV Breast Cancer AJCC v81 Anemia1 Ann Arbor Stage III Hodgkin Lymphoma1 Ann Arbor Stage III Non-Hodgkin Lymphoma1 Ann Arbor Stage IV Hodgkin Lymphoma1 Ann Arbor Stage IV Non-Hodgkin Lymphoma1 Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative1 Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive1 Brain Metastases1 Castration-Resistant Prostate Carcinoma1 Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive1 Colorectal Cancer1 Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases1 EGF-R Positive Non-Small Cell Lung Cancer1 EGFR Activating Mutation1 EGFR Gene Mutation1 EGFR Positive Non-Small Cell Lung Cancer1 Hematopoietic and Lymphoid System Neoplasm1 Locally Advanced Pancreatic Adenocarcinoma1 Lung Cancer Metastatic1

Leading sponsors

Pfizer5 Guangdong Association of Clinical Trials2 Memorial Sloan Kettering Cancer Center2 Shanghai Chest Hospital2 Fondazione Ricerca Traslazionale1 National Cancer Centre, Singapore1 OHSU Knight Cancer Institute1 Peking Union Medical College1 Samsung Medical Center1 The Netherlands Cancer Institute1

Trial status mix

COMPLETED8

UNKNOWN5

ACTIVE_NOT_RECRUITING2

RECRUITING1

TERMINATED1

Phase mix

PHASE29

PHASE15

EARLY_PHASE11

PHASE41

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.